Trial · NCT02109939
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks | from baseline to end of Week 8 | Per-Protocol | percentage of change | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change in the 16-item Quick Inventory of Depression Symptomology (QIDS-C16) Score From Baseline to 8 Weeks | from baseline to end of Week 8 | Intent-to-Treat | percentage of change | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Responders at Week 8 for HAM-D17 | Week 8 visit info | Per Protocol | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Responders at Week 12 for HAM-D17 | Week 12 visit info | |||
| SECONDARY | Percentage of Remitters at Week 12 Defined as HAM-D17 ≤7 | week 12 visit info | |||
| SECONDARY | Percentage of Remitters at Week 8 Defined as HAM-D17 ≤7 Each Treatment Group; | week 8 visit info | Per Protocol | percentage of subjects | NUMBER |
| SECONDARY | Time to Response/Remission of Depressive Symptoms Over 8 Weeks; | week 4 and 8 visit info | |||
| SECONDARY | Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 24 Weeks | Baseline to week 24 visits | Per Protocol - Due to unblinding before week 12 there was no longer a treatment as usual and guided treatment arm and it was pre-specified in the Protocol to include only the GeneSight Psychotropic Tested Arm/Group for this Outcome Measure | percentage of change | MEAN |
| SECONDARY | Percentage of Responders at Week 8 for QIDS-C16 | Week 8 visit info | Intent-to-treat | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Responders at Week 8 for PHQ-9 | Week 8 visit info | Intent-to-treat | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Remitters at Week 12 Defined as QIDS-C16 ≤5 | week 12 visit info | |||
| SECONDARY | Percentage of Remitters at Week 12 Defined as PHQ-9 <5 | week 12 visit info | |||
| SECONDARY | Percentage of Remitters at Week 12 Defined as CGI-S ≤1 | week 12 visit info | |||
| SECONDARY | Percentage of Responders at Week 12 for QIDS-C16 | Week 12 visit info | |||
| SECONDARY | Percentage of Responders at Week 12 for PHQ-9 | Week 12 visit info | |||
| SECONDARY | Percentage of Responders at Week 12 for CGI-S | Week 12 visit info | |||
| SECONDARY | Percentage of Responders at Week 12 for CGI-I | Week 12 visit info | |||
| SECONDARY | Percentage of Responders at Week 12 for CGI-EI | Week 12 visit info | |||
| SECONDARY | Percentage of Remitters at Week 8 Defined as QIDS-C16 ≤ 5 in Each Treatment Group | week 8 visit info | Intent-to-treat | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Remitters at Week 8 Defined as PHQ-9 <5 in Each Treatment Group | week 8 visit info | Intent-to-treat | percentage of subjects | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02109939/outcomes